P., Yang, Y., Nickles, D., and Cubas, R. (2019). Anti–PD-L1 treatment results in functional remodeling of the macrophage compartment. Cancer Res. 79, 1493–1506. https://doi.org/10.1158/0008-5472.CAN-18-3208.想
参考文献: 1.http://www.theguardian.com/science/2015/jun/01/immunotherapy-the-big-new-hope-for-cancer-treatment 2.http://www.cell.com/trends/cancer/abstract/S2405-8033(15)00019-9 3.http://www.sohu.com/a/313913808_100038690 4.https://www.nejm.org/doi/full/10.1056/NEJMra1703481 5.https...
参考文献：Yang Song et al, Case Report: Genetic and immune microenvironmental characteristics of a rectal cancer patient with MSS/PD-L1-negative recurrent hepatopulmonary metastasis who achieved complete remission after treatment with PD-1 inhibitor, Front Immunol. 2023 Jul 13;
P., Yang, Y., Nickles, D., and Cubas, R. (2019). Anti–PD-L1 treatment results in functional remodeling of the macrophage compartment.Cancer Res.79, 1493–1506. https://doi.org/10.1158/0008-5472.CAN-18-3208.
程序化死亡受体-1(programmed cell death-1, PD-1)/程序化死亡受体的配体(programmed cell death-ligand 1, PD-L1)免疫检查点抑制剂治疗非小细胞肺癌(non-small cell lung cancer, NSCLC)是近年来最引人注目的进展之一,但目前尚无明确的疗效预测标志物,研究者期望找到明确的标志物来筛选免疫治疗有效的患者,最大...
以上文章思路引用了《Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens》;《Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment》;《Tumor Microenvironment:A New Target for Cancer Treatment詹芸》 ...
[4]Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010 Aug 28;376(97...
过去几年里,有一类新药在学术界、癌友圈声名鹊起,被誉为冉冉升起的抗癌明星,甚至被部分“吃瓜病友”誉为:能治愈癌症的神药——它就是PD-1,说的准确些,就是PD-1抑制剂。今天咱们就来聊聊很热门的PD-1疗法。 01 肿瘤免疫治疗就等于PD-1吗? 大家都知道,...
也许最后不是因为肿瘤，而是因为治疗的不良反应患者离开了人世，这是多么让人惋惜的 参考文献：Miriam Dibos et al, Fulminant Liver Failure after Treatment with a Checkpoint Inhibitor for Gastric Cancer: A Case Report and Review of the Literature, J Clin Med. 2023 Jul 12;12(14):4641 ...
[1]Pan QZ, Zhao JJ, Liu L, et al. XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase...